C4 Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-105.0M | $-105.3M | $-132.5M | $-128.2M | $-83.9M | $-66.3M | $-34.1M |
| Depreciation & Amortization | $2.0M | $1.8M | $1.9M | $1.7M | $1.5M | $1.6M | $1.6M |
| Depreciation | $1.5M | $1.5M | $1.6M | $1.7M | $1.5M | $1.6M | $1.6M |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $19.1M | $29.7M | $27.2M | $30.0M | $21.5M | $3.4M | $1.6M |
| Net Cash from Operating Activities | $-98.7M | $-65.2M | $-106.8M | $-105.9M | $-87.0M | $-67.2M | $55.6M |
| Investing Activities | |||||||
| Capital Expenditures | $607.0K | $180.0K | $1.7M | $5.5M | $1.3M | $650.0K | $1.3M |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-8.6M | $-51.3M | $158.3M | $58.4M | $-189.3M | $-190.5M | $-1.6M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | $193.0K | $194.0K | $110.0K | $0 | — | $194.0K | $30.0K |
| Net Cash from Financing Activities | $126.4M | $45.3M | $45.5M | $1.1M | $171.4M | $348.9M | $244.0K |
| Net Change in Cash | $19.1M | $-71.1M | $97.0M | $-46.4M | $-104.9M | — | — |
| Free Cash Flow | $-99.3M | $-65.3M | $-108.5M | $-111.4M | $-88.2M | $-67.9M | $54.3M |